RECORD // Company

Amneal Pharmaceuticals, Inc.

Formerly: Atlas Holdings, Inc.

Built 2026-11-21T11:32:03Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (7 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (6)
SEC EDGAR (1)
Matched by name only, not merged (35)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • AMNEAL PHARMACEUTICALS LLC · Ct business · same registered legal name as 'Amneal Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • ATLAS HOLDINGS, LLC · Ct business · name equals 'Atlas Holdings' but other unrelated entities share it Possible match based on name, not a shared identifier. Compare the records. Compare
  • Atlas Holdings LLC · Ct business · name equals 'Atlas Holdings' but other unrelated entities share it Possible match based on name, not a shared identifier. Compare the records. Compare
  • Amneal Pharmaceuticals, LLC · Ctgov · same registered legal name as 'Amneal Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS LLC · East licences · same registered legal name as 'Amneal Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS LLC · East licences · same registered legal name as 'Amneal Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS LLC · East licences · same registered legal name as 'Amneal Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS LLC · East licences · same registered legal name as 'Amneal Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS LLC · East licences · same registered legal name as 'Amneal Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS LLC · East licences · same registered legal name as 'Amneal Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS LLC · East licences · same registered legal name as 'Amneal Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS LLC · East licences · same registered legal name as 'Amneal Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS LLC · East licences · same registered legal name as 'Amneal Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS LLC · East licences · same registered legal name as 'Amneal Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS LLC · East licences · same registered legal name as 'Amneal Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS LLC · East licences · same registered legal name as 'Amneal Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Amneal Pharmaceuticals · East licences · exact name match to 'Amneal Pharmaceuticals, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS · Epa echo · exact name match to 'Amneal Pharmaceuticals, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS · Epa echo · exact name match to 'Amneal Pharmaceuticals, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS · Epa echo · exact name match to 'Amneal Pharmaceuticals, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS · Epa echo · exact name match to 'Amneal Pharmaceuticals, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS · Epa echo · exact name match to 'Amneal Pharmaceuticals, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS CORP · Epa echo · exact name match to 'Amneal Pharmaceuticals, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS LLC · Epa echo · same registered legal name as 'Amneal Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS LLC · Epa echo · same registered legal name as 'Amneal Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS LLC · Epa echo · same registered legal name as 'Amneal Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS LLC · Epa echo · same registered legal name as 'Amneal Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS, LLC · Epa echo · same registered legal name as 'Amneal Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS · Epa rcra · exact name match to 'Amneal Pharmaceuticals, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS, INC. (lobbying via TARPLIN, DOWNS & YOUNG, LLC) · LDA lobbying · same registered legal name as 'Amneal Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS LLC · Ny corps · same registered legal name as 'Amneal Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • ATLAS HOLDINGS USA LLC · Ny corps · name equals 'Atlas Holdings' but other unrelated entities share it Possible match based on name, not a shared identifier. Compare the records. Compare
  • ATLAS HOLDINGS, LLC · Ttb permits · name equals 'Atlas Holdings' but other unrelated entities share it Possible match based on name, not a shared identifier. Compare the records. Compare
  • ATLAS HOLDINGS, LLC · Ttb permits · name equals 'Atlas Holdings' but other unrelated entities share it Possible match based on name, not a shared identifier. Compare the records. Compare
  • AMNEAL PHARMACEUTICALS, INC. · USAspending · same registered legal name as 'Amneal Pharmaceuticals, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

3 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-09 · accession 0001723128-26-000040

ItemValuePeriodFormFiledAccessionReport
Revenue$862,684,0003 months ended 2026-09-3010-Q2026-11-090001723128-26-0000402026-11-21 11:32 UTCReport an error
Net income (loss)$-21,695,0003 months ended 2026-09-3010-Q2026-11-090001723128-26-0000402026-11-21 11:32 UTCReport an error
Cash and cash equivalents$157,399,000at 2026-09-3010-Q2026-11-090001723128-26-0000402026-11-21 11:32 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001723128
Ticker
AMRX
CUSIP
03168L105
Record ID
sx:sec:0001723128

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

31 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-09SEC EDGAR company profile2026-11-21 11:32 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-09SEC EDGAR company profile2026-11-21 11:32 UTCReport an error
Fiscal year end (MMDD)12312026-11-09SEC EDGAR company profile2026-11-21 11:32 UTCReport an error
ExchangesNasdaq2026-11-09SEC EDGAR company profile2026-11-21 11:32 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$3,018,760,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-21 11:32 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$72,057,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 11:32 UTCReport an error
Total assets (at 2025-12-31)$3,678,280,0002025-12-3110-K, XBRL Assets2026-11-21 11:32 UTCReport an error
Stockholders' equity (at 2025-12-31)$-70,794,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 11:32 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$282,029,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 11:32 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$339,992,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 11:32 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$70,063,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 11:32 UTCReport an error
Long-term debt (at 2025-12-31)$2,571,876,0002025-12-3110-K, XBRL LongTermDebt2026-11-21 11:32 UTCReport an error
Operating lease liabilities (at 2025-12-31)$58,801,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 11:32 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-03)On November 3, 2026, Amneal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results for the third quarter ended September 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. The information in this report furnished pursuant to Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities…2026-11-03SEC EDGAR 8-K 0001723128-26-000035 (text as filed, excerpt)2026-11-21 11:32 UTCReport an error
8-K Item 7.01 (filed 2026-11-03)Regulation FD Disclosure Amneal will host a conference call and live webcast at 8:30 am Eastern Time today, November 3, 2026, to discuss its results. The live webcast and presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.amneal.com. To access the call through a conference line, dial 1 (833) 461-5787 (in the U.S.) with access code 304152835. A replay of the conference call will be posted shortly after the call. For a list of toll-free international numbers, visit this website: https://help.events.q4inc.com/eahc/international-dial-in-numbers. The information in this report furnished pursuant to Item 7.01 shall not be deemed…2026-11-03SEC EDGAR 8-K 0001723128-26-000035 (text as filed, excerpt)2026-11-21 11:32 UTCReport an error
8-K Item 1.01 (filed 2026-08-10)Entry into a Material Definitive Agreement. The information set forth under the Introductory Note of this Report is incorporated into this Item 1.01 by reference. First Amendment to the Third Amended and Restated Stockholders Agreement In connection with the consummation of the Acquisition, on the Closing Date, Amneal entered into a First Amendment to the Third Amended and Restated Stockholders Agreement (the “Stockholders Agreement Amendment”) with Vikram Patel, in his capacity as the Amneal Group Representative (as defined in the Third Amended and Restated Stockholders Agreement, dated November 7, 2023, by and among Amneal, Amneal Intermediate Inc., Amneal LLC, and the other parties named…2026-08-10SEC EDGAR 8-K 0001140361-26-032014 (text as filed, excerpt)2026-11-21 11:32 UTCReport an error
8-K Item 2.01 (filed 2026-08-10)Completion of Acquisition or Disposition of Assets. The information set forth in the Introductory Note of this Report is incorporated into this Item 2.01 by reference.2026-08-10SEC EDGAR 8-K 0001140361-26-032014 (text as filed, excerpt)2026-11-21 11:32 UTCReport an error
8-K Item 2.03 (filed 2026-08-10)Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in the Introductory Note and Item 1.01 of this Report is incorporated into this Item 2.03 by reference.2026-08-10SEC EDGAR 8-K 0001140361-26-032014 (text as filed, excerpt)2026-11-21 11:32 UTCReport an error
8-K Item 3.02 (filed 2026-08-10)Unregistered Sales of Equity Securities. The information set forth in the Introductory Note of this Report is incorporated into this Item 3.02 by reference. Pursuant to the Purchase Agreement, upon the Closing, Amneal issued to the Sellers 28,942,098 shares of its Class A Common Stock, par value $0.01 per share (as adjusted downward for fractional shares pursuant to the Purchase Agreement, the “Stock Consideration”). The issuance of the Stock Consideration to the Sellers was made in reliance upon the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), provided by Section 4(a)(2) thereof as a transaction by an issuer not involving…2026-08-10SEC EDGAR 8-K 0001140361-26-032014 (text as filed, excerpt)2026-11-21 11:32 UTCReport an error
8-K Item 7.01 (filed 2026-08-10)Regulation FD Disclosure. On the Closing Date, Amneal issued a press release announcing the closing of the Acquisition. A copy of the press release is attached as Exhibit 99.1 hereto.2026-08-10SEC EDGAR 8-K 0001140361-26-032014 (text as filed, excerpt)2026-11-21 11:32 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-08-03)On August 3, 2026, Amneal Pharmaceuticals, Inc.’s (the "Corporation") subsidiary, Amneal Pharmaceuticals LLC (the “Company”), and certain of the Company’s subsidiaries, as guarantors, entered into that certain Amendment No. 3 to Term Loan Credit Agreement (the “Repricing Amendment”) with JPMorgan Chase Bank, N.A., as administrative agent (the “Agent”), and the other lenders party thereto consenting to the Repricing Amendment. The Repricing Amendment amends certain terms in that certain Term Loan Credit Agreement, dated as of November 14, 2023 (the “Credit Agreement”), by and among the Company, certain of the Company’s subsidiaries party thereto as guarantors, the lenders party thereto and…2026-08-03SEC EDGAR 8-K 0001628280-26-051900 (text as filed, excerpt)2026-11-21 11:32 UTCReport an error
Largest institutional holder #1 (13F as filed): BlackRock, Inc.$459,789,8292026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:32 UTCReport an error
Largest institutional holder #2 (13F as filed): TPG GP A, LLC$213,410,9572026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:32 UTCReport an error
Largest institutional holder #3 (13F as filed): VANGUARD PORTFOLIO MANAGEMENT LLC$210,104,0542026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:32 UTCReport an error
Largest institutional holder #4 (13F as filed): Rubric Capital Management LP$176,019,5052026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:32 UTCReport an error
Largest institutional holder #5 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$133,462,2812026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:32 UTCReport an error
Largest institutional holder #6 (13F as filed): STATE STREET CORP$127,349,2722026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:32 UTCReport an error
Largest institutional holder #7 (13F as filed): DIMENSIONAL FUND ADVISORS LP$100,298,3352026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:32 UTCReport an error
Largest institutional holder #8 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$88,977,4362026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:32 UTCReport an error
Largest institutional holder #9 (13F as filed): Assenagon Asset Management S.A.$84,664,9062026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:32 UTCReport an error
Largest institutional holder #10 (13F as filed): Nantahala Capital Management, LLC$78,544,1602026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:32 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.